149 related articles for article (PubMed ID: 37327550)
1. Can breast MRI predict pathologic response following neoadjuvant chemotherapy for breast cancer? A retrospective cohort study.
Kwak L; Santa-Maria C; Di Carlo P; Mullen LA; Myers KS; Oluyemi E; Panigrahi B; Rossi J; Ambinder EB
Clin Imaging; 2023 Sep; 101():105-112. PubMed ID: 37327550
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
[TBL] [Abstract][Full Text] [Related]
4. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
5. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.
van Ramshorst MS; Loo CE; Groen EJ; Winter-Warnars GH; Wesseling J; van Duijnhoven F; Peeters MTV; Sonke GS
Breast Cancer Res Treat; 2017 Jul; 164(1):99-106. PubMed ID: 28432515
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with radiologic-pathologic discordance in magnetic resonance imaging after neoadjuvant chemotherapy for breast cancer.
Kwon MR; Chu J; Kook SH; Kim EY
Clin Imaging; 2022 Sep; 89():1-9. PubMed ID: 35654000
[TBL] [Abstract][Full Text] [Related]
8. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
9. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of response evaluation based on breast MRI after neoadjuvant treatment: a retrospective cohort study.
Bitencourt AGV; Pires BS; Calsavara VF; Negrão EMS; Souza JA; Graziano L; Guatelli CS; Makdissi FB; Sanches SM; Tavares MC; Osório CABT; De Brot M; Marques EF; Chojniak R
Eur Radiol; 2021 Dec; 31(12):9520-9528. PubMed ID: 34036420
[TBL] [Abstract][Full Text] [Related]
11. MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer.
Sener SF; Sargent RE; Lee C; Manchandia T; Le-Tran V; Olimpiadi Y; Zaremba N; Alabd A; Nelson M; Lang JE
J Surg Oncol; 2019 Nov; 120(6):903-910. PubMed ID: 31400007
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?
Thompson BM; Chala LF; Shimizu C; Mano MS; Filassi JR; Geyer FC; Torres US; de Mello GGN; da Costa Leite C
Eur Radiol; 2022 Mar; 32(3):1663-1675. PubMed ID: 34716780
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial.
Sutton EJ; Braunstein LZ; El-Tamer MB; Brogi E; Hughes M; Bryce Y; Gluskin JS; Powell S; Woosley A; Tadros A; Sevilimedu V; Martinez DF; Toni L; Smelianskaia O; Nyman CG; Razavi P; Norton L; Fung MM; Sedorovich JD; Sacchini V; Morris EA
JAMA Netw Open; 2021 Jan; 4(1):e2034045. PubMed ID: 33449096
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer phenotype influences MRI response evaluation after neoadjuvant chemotherapy.
Negrão EMS; Souza JA; Marques EF; Bitencourt AGV
Eur J Radiol; 2019 Nov; 120():108701. PubMed ID: 31610321
[TBL] [Abstract][Full Text] [Related]
15. The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes.
Kuzmova M; Cullinane C; Rutherford C; McCartan D; Rothwell J; Evoy D; Geraghty J; Prichard RS
Surg Oncol; 2023 Dec; 51():102011. PubMed ID: 37931546
[TBL] [Abstract][Full Text] [Related]
16. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
[TBL] [Abstract][Full Text] [Related]
17. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
18. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
19. MRI Performance in Detecting pCR After Neoadjuvant Chemotherapy by Molecular Subtype of Breast Cancer.
Yu N; Leung VWY; Meterissian S
World J Surg; 2019 Sep; 43(9):2254-2261. PubMed ID: 31101952
[TBL] [Abstract][Full Text] [Related]
20. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
Yoon GY; Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH; Kim JE; Kim SB
Clin Breast Cancer; 2020 Feb; 20(1):25-32. PubMed ID: 31519449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
